Regeneron, U.S. Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded Regeneron a contract worth up to $38 million to develop a mAb therapy to treat Ebola virus infection. The contract comprises initial funding of about $17 million for preclinical development and manufacturing to support an IND submission to FDA and an option to provide an additional $21 million for a Phase I trial in healthy volunteers, which is slated to start in January. Regeneron has conducted preclinical studies of the therapy, which comprises a mixture of three mAbs, in animal models of Ebola virus infection. Regeneron declined to disclose the specific targets of each mAb. ...